Healthcare ❯ Pharmaceuticals ❯ Drug Development

Cancer Treatment

Blenrep Bioconjugate Therapy Sales Projections Non-Small Cell Lung Cancer

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

The decision follows PALOMA‑3 data demonstrating pharmacokinetic noninferiority plus sharply fewer administration reactions.

Novartis Lifts Cancer-Drug Forecasts, Targets 5%–6% Sales Growth Through 2030